RE:RE:RE:Merck USA (MSD) acquires Phase 2 biotech for US$ 10.8 Bln.And as earlier posted on the US$28 Bilion "bolt-on" acquistion of Horizon by Amgen, the FTC will continue weighing in on large M&A deals which will likely prevent Pfizer's US$43 Billion proposed acquition of Seagen, as demonstrated by the FTC's decision to overturn Amgen's US$28 Billion acquistion of Horizon Therapeutics and Illumina's attempt at taking over Grail.
Conseqquently, Big Pharma will be increasingly moving on Phase 2 biotech assets in the US$ 10 -15 Billion range, as witnessed by Merck's US$10.8 Billion acquisition of Prometheus Biosciences, thus making ONCY's Phase 3 ready pelareorep a well positioned biotech asset for a similar take-over in this referenced acquisition valuation range.
Thus Pfizer remains remains an interested player for what ONCY has to offer.